Copyright
©The Author(s) 2023.
World J Hepatol. Sep 27, 2023; 15(9): 1021-1032
Published online Sep 27, 2023. doi: 10.4254/wjh.v15.i9.1021
Published online Sep 27, 2023. doi: 10.4254/wjh.v15.i9.1021
Factors | Imatinib restart1 | Imatinib withdrawal |
Grade of hepatotoxic reaction | ||
Grade 1 | + | - |
Grade 2 | +2 | - |
Grade 3 | +/-3 | +/- |
Grade 4 or presence liver transplantation or imatinib-induced liver cirrhosis or viral hepatitis reactivation | - | + |
Presence of EMR to imatinib at 3 mo = BCR-ABL1IS ≤ 10% | ||
Yes | + | - |
No | - | + |
Presence of EMR to imatinib at 6 mo = BCR-ABL1IS < 1% (if applicable4) | ||
Yes | + | - |
No | - | + |
Use of another drug that might cause liver toxicity | ||
Yes | + | - |
No | - | + |
Diagnosis of viral hepatitis established by PCR | ||
Yes | + | - |
No | - | + |
- Citation: Purwar S, Fatima A, Bhattacharyya H, Simhachalam Kutikuppala LV, Cozma MA, Srichawla BS, Komer L, Nurani KM, Găman MA. Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms. World J Hepatol 2023; 15(9): 1021-1032
- URL: https://www.wjgnet.com/1948-5182/full/v15/i9/1021.htm
- DOI: https://dx.doi.org/10.4254/wjh.v15.i9.1021